云顶新耀重磅产品艾曲莫德中国获批上市!自免领域新星崛起,开启全球商业化新篇

摩熵医药
Feb 09

2月6日,云顶新耀宣布,中国国家药监局(NMPA)正式批准艾曲莫德(VELSIPITY®,曾用名:伊曲莫德)上市,用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎(UC)成人患者。这一消息标志着云顶新耀在自身免疫性疾病赛道迎来又一里程碑式进展。全球布局多年,艾曲莫德成自免领域新星艾曲莫德是一款每日一次口服的新一代高选择性鞘氨醇-1-磷酸(S1P)受体调节剂,采用...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10